肺癌肿瘤抑制因子1在雌激素受体、孕激素受体不同表达乳腺癌患者中的临床意义  

Clinical significance of tumor suppressor in lung cancer 1 for breast cancer with different expression of estrogen receptor and progesterone receptor

作　　者：吴晓[1] 庄轶轩[1] 陈炯玉[1] 洪超群[1] 张凡[1] WU Xiao;ZHUANG Yixuan;CHEN Jiongyu;HONG Chaoqun;ZHANG Fan(Department of Central Laboratory,Cancer Hospital of Shantou University Medical College, Shantou Guangdong 515041,China)

机构地区：[1]汕头大学医学院附属肿瘤医院中心实验室,广东汕头515041

出　　处：《转化医学杂志》2017年第5期261-265,268,共6页Translational Medicine Journal

基　　金：汕头市医疗科技计划项目基金资助(汕府科[2014]62号);广东省医学科学技术研究基金资助(A2017425)

摘　　要：目的分析肺癌肿瘤抑制因子1(tumor suppressor in lung cancer 1,TSLC1)与乳腺癌临床病理和预后关系。方法收集女性乳腺癌组织125例,采用免疫组织化学技术检测TSLC1表达。结果 TSLC1主要表达在乳腺癌细胞质,其阳性率为38.4%(48/125),与患者的年龄、肿瘤大小、淋巴结转移、临床分期、人类表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)表达无关,而与雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)表达相关(P<0.001)。ER^+(阳性)患者TSLC1阳性率低于ER-(阴性)患者[28.4%(25/88)与62.2%(23/37)];同样,PR^+患者TSLC1阳性率低于PR^-患者[24.3%(17/70)与56.4%(31/55)]。Z检验显示在ER^+PR^-的乳腺癌患者中TSLC1^-和TSLC1^+患者3年生存率差异有统计学意义(83.3%与14.3%,P=0.007),总体生存曲线差异有统计学意义(P=0.003)。Cox多因素回归分析,TSLC1不是ER^+PR^-乳腺癌患者独立的危险预后因素(比值比10.696,95%可信区间0.988~115.843,P=0.051)。结论 TSLC1在乳腺癌致病机制中与ER、PR相关,可作为临床ER^+PR^-乳腺癌患者新的预后指标。Objective To study the protein expression of tumor suppressor in lung cancer 1(TSLC1)to understand its relationship with clinicopathological parameters and its influence on the prognosis of human breast cancer.Methods We collected tumor tissues from 125 female patients with breast cancer treated at the Cancer Hospital of Shantou University Medical College from October 2001 to December 2010.Immunohistochemistry was performed to detect the protein expression of TSLC1 in breast tumors,and the chi-square test was used to study the relationship between the TSLC1 expression and clinicopathological parameters.The Z test,Kaplan-Meier method and Cox regression model were conducted to study the influence of TSLC1 on the prognosis of breast cancer.Results TSLC1 protein was expressed primarily in the cytoplasm.The positive rate of TSLC1 in 125 breast tumors was 38.4%(48/125).The chi-square test revealed that the TSLC1 expression was not related to age(P=0.766),tumor size(P=0.485),lymph node metastasis(P=0.894),clinical stages(P=0.624),and human epidermal growth factor receptor-2(HER-2)expression(P=0.388),but significantly associated with estrogen receptor(ER)and progesterone receptor(PR)(P<0.001).Out of 88 ER+patients,25 patients were stained TSLC1+(28.4%),which is signi-ficantly lower than that of ER-patients(62.2%,23/37).Similarly,out of 70 PR+patients,17 patients were stained TSLC1+(24.3%),and significantly lower than that of PR-patients(56.4%,31/55).The overall 3-years survival rates were significantly different between the TSLC1-group and the TSLC1+group(83.3%vs.14.3%,P=0.007),and the survival curves in these two groups were significantly different(P=0.003).Multivariate Cox regression model demonstrated that TSLC1[odds ratio(OR)10.696,95%confidence intervals(CI)0.988-115.843,P=0.051)]were not the independent unfavorable prognostic factors for ER+PR-breast cancer.Conclusion TSLC1 is associated with ER and PR in the progression of breast cancer,and could be a novel prognostic factor for ER+PR-breast cancer.

关 键 词：乳腺癌 肺癌肿瘤抑制因子1 雌激素受体 孕激素受体 免疫组织化学 预后 

分 类 号：R737.9[医药卫生—肿瘤]